Latest Period
n/a
Security Snapshot
Sofgen Pharma S.A. - Ordinary Shares, nominal value of $0.01 per share (PROCF) Institutional Ownership
CUSIP: L7756P102
13F Institutional Holders and Ownership History from Q3 2021 to Q1 2025
Institutions Reporting
Shares (Excl. Options)
Price
$0.01
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Ordinary Shares, nominal value of $0.01 per share
- Symbol
- PROCF
- Shares outstanding
- 2,461,355,158
- SEC-reported price per share
- $0.01
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- PROCF - Sofgen Pharma S.A. - Ordinary Shares, nominal value of $0.01 per share is tracked under CUSIP L7756P102.
- Latest finished 13F holder period is not available.
- 5 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 5 to 0 between Q4 2024 and Q1 2025.
- SEC-reported value moved from $1,613,042 to $0.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Schedule 13D/G
Open SEC evidence
Ownership context comes from Schedule 13D/G and available holder history for this CUSIP.
Security key
L7756P102
Latest holder period
n/a
13F holders
13D/G owners
5
CIK / CUSIP context first
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP L7756P102:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
5
Security
PROCF
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Hoche Partners Pharma Holding S.A. | 84% | $2,867,018,231 | 2,077,549,443 | Hoche Partners Pharma Holding S.A. | 16 Apr 2025 | |||
| Saint Thomas Commercial S.A. | 84% | $2,867,018,231 | 2,077,549,443 | Saint Thomas Commercial S.A. | 09 Apr 2025 | |||
| Flying Fish Ventures L.P. | 84% | $2,867,018,231 | 2,077,549,443 | Flying Fish Ventures, L.P. | 09 Apr 2025 | |||
| Chemo Project, S.A. | 53% | $1,800,235,163 | 1,304,518,234 | Chemo Project, S.A. | 09 Apr 2025 | |||
| Becaril S.A. | 53% | $1,800,235,163 | 1,304,518,234 | Becaril S.A. | 09 Apr 2025 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
15
Latest
n/a
Rows shown
1-15 of 15
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q1 | 0 | $0 | -$1,613,042 | $0.01 | 0 |
| 2024 Q4 | 221,439 | $1,613,042 | +$1,242,140 | $2.34 | 5 |
| 2024 Q3 | 166,189 | $367,179 | -$32,329 | $2.20 | 5 |
| 2024 Q2 | 179,063 | $452,581 | +$209,627 | $2.51 | 7 |
| 2024 Q1 | 89,855 | $270,384 | -$634,351 | $2.90 | 9 |
| 2023 Q4 | 243,277 | $990,304 | +$226,732 | $4.07 | 11 |
| 2023 Q3 | 62,661 | $226,832 | -$33,859 | $3.62 | 8 |
| 2023 Q2 | 71,985 | $342,514 | -$629,823 | $3.97 | 9 |
| 2023 Q1 | 220,633 | $994,941 | -$1,900,378 | $4.51 | 6 |
| 2022 Q4 | 641,937 | $3,369,033 | -$2,182,064 | $5.25 | 7 |
| 2022 Q3 | 1,067,698 | $7,473,000 | -$5,257,642 | $7.00 | 8 |
| 2022 Q2 | 1,668,061 | $15,545,000 | -$1,097,988 | $9.32 | 10 |
| 2022 Q1 | 1,795,515 | $15,261,000 | -$1,244,081 | $8.50 | 9 |
| 2021 Q4 | 1,939,037 | $18,861,000 | -$318,530 | $9.75 | 12 |
| 2021 Q3 | 1,941,513 | $19,803,000 | +$19,803,000 | $10.20 | 15 |